Tilray Brands, Inc. - Common Stock (TLRY)

In a paradoxical display of market confidence, shares of Tilray Brands (NASDAQ:TLRY) surged over 8% on Wednesday following the release of its fiscal third-quarter 2026 financial results. While the company delivered a "record" revenue performance of $206.7 million, outstripping analyst estimates of $201.3 million, it fell significantly

Tilray (TLRY) shares jump in premarket after record Q3 results. Adjusted EPS of $0.02 beats estimates as revenue hits a record $206.7M.

Tilray Brands Inc (TLRY) shares are climbing in Wednesday's premarket as the company prepares to report Q3 fiscal 2026 results.

TLRY premarket gains follow Shock Top's first high-ABV beer launch. See how Tilray Brands is innovating in the craft beverage segment.

Tilray expanded its medical cannabis portfolio in Australia, but market weakness overshadows the company's push into a key growth market.

The stock has been a wealth destroyer for a while.

Tilray Brands' business has become larger over the years as it has expanded into beverages.

Tilray slipped Thursday despite expanding its Germany healthcare partnership, as investors weighed the strategic move against broader market weakness and company-specific pressure.

Tilray (TLRY) shares rise premarket as the company launches Pub Light beer and expands its global beverage portfolio. Get the latest details.

Tilray has been loading up on acquisitions over the years, which have expanded and diversified its operations.

Tilray scales its international footprint with BrewDog's Australian operations, targeting new retail markets in Japan and the APAC region.

Tilray Brands is losing money as it attempts to build a consumer staples business, while this industry giant throws off tons of cash.

Tilray said that it has acquired the BrewDog brand and related intellectual property, UK brewing operations and eleven strategic brewpubs in the United Kingdom and Ireland.

Tilray shares fall after closing $44 million BrewDog deal, targeting $1.2 billion annual revenue amid market weakness and stock pressure.

Abbott Laboratories is delivering double-digit percentage earnings growth along with a dependable dividend.

Tilray Brands is expanding its business at a rapid clip, but there are risks associated with this growth effort.

Holding this stock has been a painful lesson about cutting your losses.

Tilray is moving in the right direction, but it still isn't a sustainably profitable business.

Don't bet on either one to pull that off.

The multi-year licensing agreement with the Danish brewing giant will allow Tilray to produce and distribute several Carlsberg beer brands in all U.S. channels starting Jan. 1, 2027.

Tilray stock rose after it landed an exclusive multi-year U.S. licensing deal to produce and distribute several Carlsberg-branded beers.

The company isn't in good financial shape, and there's still plenty of risk with the stock.

Tilray shares edged higher in premarket trading after the company rebranded its Italy unit as Tilray Medical Italia and highlighted expansion plans in the regulated medical cannabis market.